Abstract:The ubiquitin-proteasome system (UPS) promotes the timely degradation of short-lived proteins with key regulatory roles in a vast array of biological processes, such as cell cycle progression, oncogenesis and genome integrity. Thus, abnormal regulation of UPS disrupts the protein homeostasis and causes many human diseases, particularly cancer. Indeed, the FDA approval of bortezomib, the first class of general proteasome inhibitor, for the treatment of multiple myeloma, demonstrated that the UPS can be an attractive anti-cancer target. However, normal cell toxicity associated with bortezomib, resulting from global inhibition of protein degradation, promotes the focus of drug discovery efforts on targeting enzymes upstream of the proteasome for better specificity. E3 ubiquitin ligases, particularly those known to be activated in human cancer, become an attractive choice. Cullin-RING Ligases (CRLs) with multiple components are the largest family of E3 ubiquitin ligases and are responsible for ubiquitination of similar to 20% of cellular proteins degraded through UPS. Activity of CRLs is dynamically regulated and requires the RING component and cullin neddylation. In this review, we will introduce the UPS and CRL E3s and discuss the biological processes regulated by each of eight CRLs through substrate degradation. We will further discuss how cullin neddylation controls CRL activity, and how CRLs are being validated as the attractive cancer targets by abrogating the RING component through genetic means and by inhibiting cullin neddylation via MLN4924, a small molecule indirect inhibitor of CRLs, currently in several Phase I clinical trials. Finally, we will discuss current efforts and future perspectives on the development of additional inhibitors of CRLs by targeting E2 and/or E3 of cullin neddylation and CRL-mediated ubiquitination as potential anti-cancer agents.

CRL4BDCAF11 E3 ligase targets p21 for degradation to control cell cycle progression in human osteosarcoma cells

Activation of TNF‐α/NF‐κB Axis Enhances CRL4BDCAF11 E3 Ligase Activity and Regulates Cell Cycle Progression in Human Osteosarcoma Cells

CUL4B Promotes Proliferation and Inhibits Apoptosis of Human Osteosarcoma Cells.

Increased Cul1 Expression Promotes Melanoma Cell Proliferation Through Regulating P27 Expression

MicroRNA-300 Regulates the Ubiquitination of PTEN Through the CRL4BDCAF13 E3 Ligase in Osteosarcoma Cells

The E3 Ligase Ring1 Targets P53 For Degradation And Promotes Cancer Cell Proliferation And Survival

Small Molecule TSC01682 Inhibits Osteosarcoma Cell Growth by Specifically Disrupting the CUL4B-DDB1 Interaction and Decreasing the Ubiquitination of CRL4B E3 Ligase Substrates.

CRL4B Interacts with and Coordinates the SIN3A-HDAC Complex to Repress CDKN1A and Drive Cell Cycle Progression

CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma

The emerging role for Cullin 4 family of E3 ligases in tumorigenesis

CRL4B promotes tumorigenesis by coordinating with SUV39H1/HP1/DNMT3A in DNA methylation-based epigenetic silencing

Cullin 4-DCAF Proteins in Tumorigenesis

CRL4-DCAF8L1 Regulates BRCA1 and BARD1 Protein Stability

URG4 Mediates Cell Proliferation and Cell Cycle in Osteosarcoma Via GSK3β/β-catenin/cyclin D1 Signaling Pathway

CRL4B promotes tumorigenesis by coordinating with SUV39H1|[sol]|HP1|[sol]|DNMT3A in DNA methylation-based epigenetic silencing

CRL4B catalyzes H2AK119 monoubiquitination and coordinates with PRC2 to promote tumorigenesis.

Cullin-RING Ligases as attractive anti-cancer targets.

Involvement of CUL4 ubiquitin E3 ligases in regulating CDK inhibitors Dacapo/p27(Kip1) and cyclin E degradation

Targeting Cul3-scaffold E3 ligase complex <i>via</i> KLHL substrate adaptors for cancer therapy

CRL4BRBBP7 Targets HUWE1 for Ubiquitination and Proteasomal Degradation.

CRL4ADTL Degrades DNA-PKcs to Modulate NHEJ Repair and Induce Genomic Instability and Subsequent Malignant Transformation